Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

MBX Biosciences, Inc.

MBX · Nasdaq · CIK 0001776111 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

10 Form 4 transaction lines observed in the same window
5 sales · 5 option, withholding, award, gift or other lines

Last qualifying purchase2026-03-13 · Hawryluk P. Kent · $525.6K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Azoulay SalomonChief Medical Officer
▼○▼▼
Hoerter Steven L.Director
○○
Hawryluk P. KentPresident & CEO
▼
Smither John WChief Financial Officer
○
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-03-13 · Hawryluk P. Kent.

Recent Form 4 activity

2Purchases
5Sales
10Other Form 4 lines
14SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING5 sale line(s) · context only
OTHER5 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,466,280
Previous report
4,129,859
Avg daily volume
653,352
Days to cover
6.8

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-03-13Hawryluk P. KentPurchase (P)Common Stock18,500USD 28.41USD 525,585SEC filing ↗
2025-10-20Hawryluk P. KentPurchase (P)Common Stock20,000USD 13.64USD 272,800SEC filing ↗
2025-10-17Hoerter Steven L.Purchase (P)Common Stock20,000USD 13.25USD 265,000SEC filing ↗
2025-09-26FHMLS X, L.L.C.; FHMLS X, L.P.; Frazier Life Sciences X, L.P.; Heron Patrick J; Topper James NPurchase (P)Common Stock666,666USD 18.00USD 11,999,988SEC filing ↗
2025-04-08Pescovitz Ora H.Purchase (P)Common Stock7,693USD 5.89USD 45,312SEC filing ↗
2025-02-18ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock143,170USD 10.84USD 1,551,963SEC filing ↗
2025-02-18GORDON CARL LPurchase (P)Common Stock143,170USD 10.84USD 1,551,963SEC filing ↗
2025-02-14ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock47,502USD 9.87USD 468,793SEC filing ↗
2025-02-14GORDON CARL LPurchase (P)Common Stock47,502USD 9.87USD 468,793SEC filing ↗
2025-02-04Hawryluk P. KentPurchase (P)Common Stock50,000USD 10.69USD 534,500SEC filing ↗
2024-09-16Yang RickPurchase (P)Common Stock500,000USD 16.00USD 8,000,000SEC filing ↗
2024-09-16Walker Paul EdwardPurchase (P)Common Stock500,000USD 16.00USD 8,000,000SEC filing ↗
2024-09-16SANDELL SCOTT DPurchase (P)Common Stock500,000USD 16.00USD 8,000,000SEC filing ↗
2024-09-16ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock750,000USD 16.00USD 12,000,000SEC filing ↗
2024-09-16NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P.Purchase (P)Common Stock500,000USD 16.00USD 8,000,000SEC filing ↗

Form 4 evidence

17 transaction lines in the latest 365-day window; 78 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Azoulay SalomonSale (S)Common Stock370USD 65.77USD 24,335SEC filing ↗
2026-08-03Smither John WAward / grant (A)Common Stock28,000USD 0.00USD 0SEC filing ↗
2026-08-03Hoerter Steven L.Award / grant (A)Common Stock71,000USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (15 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Azoulay SalomonSale (S)Common Stock370USD 65.77USD 24,335SEC filing ↗
2026-08-03Smither John WAward / grant (A)Common Stock28,000USD 0.00USD 0SEC filing ↗
2026-08-03Hoerter Steven L.Award / grant (A)Common Stock71,000USD 0.00USD 0SEC filing ↗
2026-05-08Azoulay SalomonSale (S)Common Stock70,003USD 38.36USD 2,685,515SEC filing ↗
2026-05-08Azoulay SalomonOption exercise / conversion (M)Common Stock70,003USD 11.65USD 815,348SEC filing ↗
2026-05-06Hawryluk P. KentSale (S)Common Stock607USD 29.54USD 17,931SEC filing ↗
2026-05-06Azoulay SalomonSale (S)Common Stock231USD 29.54USD 6,824SEC filing ↗
2026-05-01Hoerter Steven L.Award / grant (A)Common Stock11,938USD 0.00USD 0SEC filing ↗
2026-03-13Hawryluk P. KentPurchase (P)Common Stock18,500USD 28.41USD 525,585SEC filing ↗
2026-02-26Hawryluk P. KentOption exercise / conversion (M)Common Stock28,768USD 16.00USD 460,288SEC filing ↗
2026-02-02Hawryluk P. KentAward / grant (A)Common Stock35,250USD 0.00USD 0SEC filing ↗
2026-02-02Bartram RichardAward / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2026-02-02Azoulay SalomonAward / grant (A)Common Stock15,000USD 0.00USD 0SEC filing ↗
2025-10-24Hawryluk P. KentOption exercise / conversion (M)Common Stock182,859USD 3.25USD 594,292SEC filing ↗
2025-10-20Hawryluk P. KentPurchase (P)Common Stock20,000USD 13.64USD 272,800SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerMBX
CIK0001776111
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history78 transaction lines from 2024-09-16 to 2026-08-04
31 P purchase lines · 5 S sale lines · 42 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.